Los Angeles Capital Management LLC Makes New Investment in ChromaDex Co. (NASDAQ:CDXC)

Los Angeles Capital Management LLC purchased a new position in shares of ChromaDex Co. (NASDAQ:CDXC - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 218,528 shares of the company's stock, valued at approximately $1,159,000. Los Angeles Capital Management LLC owned 0.29% of ChromaDex as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in CDXC. BSW Wealth Partners acquired a new position in ChromaDex in the third quarter valued at $324,000. Barclays PLC increased its stake in shares of ChromaDex by 322.1% during the 3rd quarter. Barclays PLC now owns 70,072 shares of the company's stock valued at $256,000 after acquiring an additional 53,472 shares during the last quarter. Sargent Investment Group LLC purchased a new position in shares of ChromaDex during the 4th quarter worth about $263,000. FMR LLC acquired a new stake in shares of ChromaDex in the third quarter worth approximately $55,000. Finally, JPMorgan Chase & Co. grew its holdings in ChromaDex by 11.1% in the third quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company's stock valued at $1,211,000 after purchasing an additional 33,150 shares during the period. Institutional investors and hedge funds own 15.41% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on CDXC shares. Roth Mkm lifted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. LADENBURG THALM/SH SH lifted their target price on ChromaDex from $6.80 to $8.10 and gave the company a "buy" rating in a report on Wednesday. Finally, StockNews.com upgraded ChromaDex from a "buy" rating to a "strong-buy" rating in a research note on Monday, February 24th.

Remove Ads

Insider Buying and Selling at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares in the company, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.64% of the stock is currently owned by corporate insiders.

ChromaDex Stock Up 52.7 %

Shares of ChromaDex stock traded up $2.95 during trading hours on Wednesday, hitting $8.55. The company's stock had a trading volume of 18,687,195 shares, compared to its average volume of 823,760. The company has a market capitalization of $653.07 million, a PE ratio of 855.86 and a beta of 2.21. The business has a fifty day moving average of $5.68 and a 200 day moving average of $5.13. ChromaDex Co. has a 1-year low of $1.57 and a 1-year high of $9.18.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.